- Moise K Jr. Umbilical Cord Stem Cells, Obstetrics Gynecology, 2005; 106(6):1393-1407
- Nietfield JJ, Pasquini MC, Logan BR, Verter, Horowitz MM. Lifetime Probabilities of a Hematopietic Stem Cell Transplantation in the US, Biology Blood and Marrow Transplant, 2008; 14:316-322.
- Based on a 3/6 HLA match.
- Stroke: Ding DC, Shyu WC, Chiang MF et al. Enhancement of Neuroplasticity through Upregulation of B1-integrin in Human Umbilical Cord Derived Stromal Stem Cell Implanted Stroke Model, Neurobiology Dis. 2007; 27(3):339-353. E-publication 2007 June 18.
- Parkinson’s Disease: Fu YS, Cheng YC, Lin MY, et al. Conversion of Human Umbilical Cord Mesenchymal Stem Cells in Wharton’s Jelly To Dopaminergic Neurons in Vitro: Potential Therapeutic Application For Parkinson’s Disease, Stem Cells. 2006; 24(1):115-124. E-publication 2005 August.
- Rheumatoid Arthritis: Liu Y Mu R Wang S et al. Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis, Arthritis Res Ther. 2010; 12(6):R210
- Sports Injuries (cartilage): Wang L. Tran 1, Seshareddy K et al. A Comparison of Human Bone Marrow-Derived Mesenchymal Stem Cells and Human Umbilical Cord Derived Mesenchymal Stromal Cells for Cartilage Tissue Engineering, Tissue Eng. 2009; 15(8)(pt A): 2259-2266.
- Type 1 Diabetes: Anzalone R, Lo Iacono M, Loria T, et al. Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes. Stem Cell Rev. October 23, 2010 E-publication.
- Lung Cancer: Maurya DK, Doi C, Kawabata A, et al. Therapy With Un-engineered Naïve Rat Umbilical Cord Blood Matrix Stem Cells Markedly Inhibits Growth of Murine Lung Adenocarcinoma, BMC Cancer, 2010;10-590.
- Data on file as of February 2014.
- Accreditations current as of February 2014.
- Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Human and Health Services, Guidance for the Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoetic Reconstitution for Specified Indications, October 2009.
- Data on file for CariCord and numbers from company websites ViaCord (268) and CBR (262) as of February 2014.
- Discount applies when cord blood and cord tissue banking are chosen with a prepaid storage plan. Prices effective as of February 2014
General Disclaimer: Most of the diseases currently treated with cord blood stem cells are genetic diseases. Banking cord blood does not guarantee that your physicians will choose it as first line course of treatment over a sibling donor or autologous donor depending on the diseases being treated and other factors in consideration of a transplant. Only a treating physician can determine when it should be used on a case by case basis. Cord tissue research is pre-clinical and may have potential in the future but is not used in treatments in humans currently.